Community-based surveys for Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions in selected regions of mainland Tanzania.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
04 Nov 2020
Historique:
received: 27 06 2020
accepted: 22 10 2020
entrez: 5 11 2020
pubmed: 6 11 2020
medline: 10 6 2021
Statut: epublish

Résumé

Histidine-rich protein 2 (HRP2)-based malaria rapid diagnostic tests (RDTs) are effective and widely used for the detection of wild-type Plasmodium falciparum infections. Although recent studies have reported false negative HRP2 RDT results due to pfhrp2 and pfhrp3 gene deletions in different countries, there is a paucity of data on the deletions of these genes in Tanzania. A community-based cross-sectional survey was conducted between July and November 2017 in four regions: Geita, Kigoma, Mtwara and Ruvuma. All participants had microscopy and RDT performed in the field and provided a blood sample for laboratory multiplex antigen detection (for Plasmodium lactate dehydrogenase, aldolase, and P. falciparum HRP2). Samples showing RDT false negativity or aberrant relationship of HRP2 to pan-Plasmodium antigens were genotyped to detect the presence/absence of pfhrp2/3 genes. Of all samples screened by the multiplex antigen assay (n = 7543), 2417 (32.0%) were positive for any Plasmodium antigens while 5126 (68.0%) were negative for all antigens. The vast majority of the antigen positive samples contained HRP2 (2411, 99.8%), but 6 (0.2%) had only pLDH and/or aldolase without HRP2. Overall, 13 samples had an atypical relationship between a pan-Plasmodium antigen and HRP2, but were positive by PCR. An additional 16 samples with negative HRP2 RDT results but P. falciparum positive by microscopy were also chosen for pfhrp2/3 genotyping. The summation of false negative RDT results and laboratory antigen results provided 35 total samples with confirmed P. falciparum DNA for pfhrp2/3 genotyping. Of the 35 samples, 4 (11.4%) failed to consistently amplify positive control genes; pfmsp1 and pfmsp2 and were excluded from the analysis. The pfhrp2 and pfhrp3 genes were successfully amplified in the remaining 31 (88.6%) samples, confirming an absence of deletions in these genes. This study provides evidence that P. falciparum parasites in the study area have no deletions of both pfhrp2 and pfhrp3 genes. Although single gene deletions could have been missed by the multiplex antigen assay, the findings support the continued use of HRP2-based RDTs in Tanzania for routine malaria diagnosis. There is a need for the surveillance to monitor the status of pfhrp2 and/or pfhrp3 deletions in the future.

Sections du résumé

BACKGROUND BACKGROUND
Histidine-rich protein 2 (HRP2)-based malaria rapid diagnostic tests (RDTs) are effective and widely used for the detection of wild-type Plasmodium falciparum infections. Although recent studies have reported false negative HRP2 RDT results due to pfhrp2 and pfhrp3 gene deletions in different countries, there is a paucity of data on the deletions of these genes in Tanzania.
METHODS METHODS
A community-based cross-sectional survey was conducted between July and November 2017 in four regions: Geita, Kigoma, Mtwara and Ruvuma. All participants had microscopy and RDT performed in the field and provided a blood sample for laboratory multiplex antigen detection (for Plasmodium lactate dehydrogenase, aldolase, and P. falciparum HRP2). Samples showing RDT false negativity or aberrant relationship of HRP2 to pan-Plasmodium antigens were genotyped to detect the presence/absence of pfhrp2/3 genes.
RESULTS RESULTS
Of all samples screened by the multiplex antigen assay (n = 7543), 2417 (32.0%) were positive for any Plasmodium antigens while 5126 (68.0%) were negative for all antigens. The vast majority of the antigen positive samples contained HRP2 (2411, 99.8%), but 6 (0.2%) had only pLDH and/or aldolase without HRP2. Overall, 13 samples had an atypical relationship between a pan-Plasmodium antigen and HRP2, but were positive by PCR. An additional 16 samples with negative HRP2 RDT results but P. falciparum positive by microscopy were also chosen for pfhrp2/3 genotyping. The summation of false negative RDT results and laboratory antigen results provided 35 total samples with confirmed P. falciparum DNA for pfhrp2/3 genotyping. Of the 35 samples, 4 (11.4%) failed to consistently amplify positive control genes; pfmsp1 and pfmsp2 and were excluded from the analysis. The pfhrp2 and pfhrp3 genes were successfully amplified in the remaining 31 (88.6%) samples, confirming an absence of deletions in these genes.
CONCLUSIONS CONCLUSIONS
This study provides evidence that P. falciparum parasites in the study area have no deletions of both pfhrp2 and pfhrp3 genes. Although single gene deletions could have been missed by the multiplex antigen assay, the findings support the continued use of HRP2-based RDTs in Tanzania for routine malaria diagnosis. There is a need for the surveillance to monitor the status of pfhrp2 and/or pfhrp3 deletions in the future.

Identifiants

pubmed: 33148255
doi: 10.1186/s12936-020-03459-3
pii: 10.1186/s12936-020-03459-3
pmc: PMC7640459
doi:

Substances chimiques

Antigens, Protozoan 0
HRP-2 antigen, Plasmodium falciparum 0
HRP3 protein, Plasmodium falciparum 0
Protozoan Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

391

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Developing Excellence in Leadership and Training (DELTAS) Africa Initiative, of the African Academy of Sciences (AAS).
ID : DELGEME grant 107740/Z/15/Z)

Références

Malar J. 2017 Mar 20;16(1):123
pubmed: 28320390
Malar J. 2013 Jan 24;12:34
pubmed: 23347727
Nat Rev Microbiol. 2006 Sep;4(9):682-95
pubmed: 16912713
J Infect Dis. 2017 Jul 1;216(1):36-44
pubmed: 28177502
Proc Natl Acad Sci U S A. 1987 Nov;84(21):7672-6
pubmed: 3313401
PLoS One. 2017 Mar 16;12(3):e0171150
pubmed: 28301474
Proc Natl Acad Sci U S A. 1986 Aug;83(16):6065-9
pubmed: 3016741
Malar J. 2019 Apr 11;18(1):130
pubmed: 30971231
Malar J. 2019 Mar 25;18(1):98
pubmed: 30909912
Malar J. 2017 Nov 7;16(1):451
pubmed: 29115966
Clin Microbiol Rev. 2008 Jan;21(1):97-110
pubmed: 18202438
Parasitology. 1987 Oct;95 ( Pt 2):209-27
pubmed: 3320887
PLoS One. 2011 Apr 06;6(4):e18419
pubmed: 21494674
Malar J. 2014 Jul 22;13:283
pubmed: 25052298
PLoS One. 2017 Jun 22;12(6):e0179178
pubmed: 28640824
Malar J. 2018 Dec 5;17(1):452
pubmed: 30518365
Malar J. 2015 Jan 21;14:19
pubmed: 25604310
Am J Trop Med Hyg. 2012 Feb;86(2):194-8
pubmed: 22302847
PLoS One. 2013 Sep 23;8(9):e74269
pubmed: 24086328
J Infect Dis. 2005 Sep 1;192(5):870-7
pubmed: 16088837
Parasit Vectors. 2015 Jul 22;8:388
pubmed: 26198252
Clin Microbiol Infect. 2019 May;25(5):580-585
pubmed: 30267926
J Clin Microbiol. 2006 Aug;44(8):2773-8
pubmed: 16891491
Malar J. 2017 Mar 6;16(1):105
pubmed: 28264689
Malar J. 2012 Aug 16;11:276
pubmed: 22898068
J Infect Dis. 2019 Sep 26;220(9):1444-1452
pubmed: 31249999
Clin Microbiol Infect. 2013 May;19(5):399-407
pubmed: 23438048
PLoS One. 2016 Aug 12;11(8):e0157949
pubmed: 27518538
J Infect Dis. 2019 Jan 9;219(3):437-447
pubmed: 30202972
PLoS One. 2010 Jan 25;5(1):e8091
pubmed: 20111602
EBioMedicine. 2020 May;55:102757
pubmed: 32403083
Malar J. 2011 Jun 26;10:176
pubmed: 21703016
Sci Rep. 2013 Sep 30;3:2797
pubmed: 24077522
J Clin Microbiol. 2012 Apr;50(4):1397-405
pubmed: 22259210
Malar J. 2011 Sep 29;10:286
pubmed: 21957869
Am J Trop Med Hyg. 2010 Dec;83(6):1238-41
pubmed: 21118927
PLoS One. 2012;7(8):e43094
pubmed: 22952633
Malar J. 2012 May 03;11:152
pubmed: 22554149
Sci Rep. 2017 Nov 7;7(1):14718
pubmed: 29116127
Acta Trop. 2015 Dec;152:26-31
pubmed: 26297799
Clin Microbiol Rev. 2002 Jan;15(1):66-78
pubmed: 11781267
Malar J. 2014 Nov 26;13:462
pubmed: 25428550

Auteurs

Catherine Bakari (C)

Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
National Institute for Medical Research, Tanga Research Centre, Tanga, Tanzania.

Sophie Jones (S)

Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Williams Consulting, Baltimore, MD, USA.

Gireesh Subramaniam (G)

Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Oak Ridge Institute for Science and Education, Atlanta, GA, USA.

Celine I Mandara (CI)

National Institute for Medical Research, Tanga Research Centre, Tanga, Tanzania.
Kilimanjaro Christian Medical University College, Moshi, Tanzania.

Mercy G Chiduo (MG)

National Institute for Medical Research, Tanga Research Centre, Tanga, Tanzania.

Susan Rumisha (S)

National Institute for Medical Research, Dar es Salaam, Tanzania.

Frank Chacky (F)

National Malaria Control Programme (NMCP), Dodoma, Tanzania.

Fabrizio Molteni (F)

National Malaria Control Programme (NMCP), Dodoma, Tanzania.

Renata Mandike (R)

National Malaria Control Programme (NMCP), Dodoma, Tanzania.

Sigsbert Mkude (S)

National Malaria Control Programme (NMCP), Dodoma, Tanzania.

Ritha Njau (R)

World Health Organization (WHO) Country Office, Dar es Salaam, Tanzania.

Camelia Herman (C)

Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.
CDC Foundation (CDCF), Atlanta, GA, USA.

Douglas P Nace (DP)

Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Ally Mohamed (A)

National Malaria Control Programme (NMCP), Dodoma, Tanzania.

Venkatachalam Udhayakumar (V)

Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Caleb K Kibet (CK)

Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.

Steven G Nyanjom (SG)

Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.

Eric Rogier (E)

Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Deus S Ishengoma (DS)

National Institute for Medical Research, Dar es Salaam, Tanzania. deusishe@yahoo.com.
Faculty of Pharmaceutical Sciences, Monash University, Melbourne, Australia. deusishe@yahoo.com.
Harvard T.H Chan School of Public Health, Boston, MA, USA. deusishe@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH